TScan Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at March 31, 2023 | 19,480,729 | $2 | 4,745,225 | $1 | $258,957 | $(180,942) | $78,018 |
| Exercise of stock options | 305,678 | - | - | - | 682 | - | 682 |
| Issuance of common stock, net of offering costs | 23,287,134 | 2 | - | - | 42,412 | - | 42,414 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 92,318 | - | 92,318 |
| Conversion of non-voting common stock to voting common stock | 468,637 | - | (468,637) | - | - | - | - |
| Stock-based compensation expense | - | - | - | - | 1,220 | - | 1,220 |
| Net loss | - | - | - | - | - | (24,045) | (24,045) |
| Balances at June 30, 2023 | 43,542,178 | $4 | 4,276,588 | $1 | $395,589 | $(204,987) | $190,607 |
| Balances at March 31, 2024 | 43,628,149 | $4 | 4,276,588 | $1 | $400,701 | $(277,739) | $122,967 |
| Exercise of stock options | 69,941 | - | - | - | 183 | - | 183 |
| Issuance of common stock, net of offering costs | 4,958,068 | 1 | - | - | 33,130 | - | 33,131 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 128,272 | - | 128,272 |
| Stock-based compensation expense | - | - | - | - | 2,329 | - | 2,329 |
| Net loss | - | - | - | - | - | (31,661) | (31,661) |
| Balances at June 30, 2024 | 48,656,158 | $5 | 4,276,588 | $1 | $564,615 | $(309,400) | $255,221 |
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at January 1, 2023 | 19,082,820 | $2 | 5,143,134 | $1 | $257,810 | $(158,379) | $99,434 |
| Exercise of stock options | 305,678 | - | - | - | 682 | - | 682 |
| Issuance of common stock, net of offering costs | 23,287,134 | 2 | - | - | 42,412 | - | 42,414 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 92,318 | - | 92,318 |
| Conversion of non-voting common stock to voting common stock | 866,546 | - | (866,546) | - | - | - | - |
| Stock-based compensation expense | - | - | - | - | 2,367 | - | 2,367 |
| Net loss | - | - | - | - | - | (46,608) | (46,608) |
| Balances at June 30, 2023 | 43,542,178 | $4 | 4,276,588 | $1 | $395,589 | $(204,987) | $190,607 |
| Balances at January 1, 2024 | 43,552,941 | $4 | 4,276,588 | $1 | $398,459 | $(247,597) | $150,867 |
| Exercise of stock options | 145,149 | - | - | - | 442 | - | 442 |
| Issuance of common stock, net of offering costs | 4,958,068 | 1 | - | - | 33,130 | - | 33,131 |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 128,272 | - | 128,272 |
| Stock-based compensation expense | - | - | - | - | 4,312 | - | 4,312 |
| Net loss | - | - | - | - | - | (61,803) | (61,803) |
| Balances at June 30, 2024 | 48,656,158 | $5 | 4,276,588 | $1 | $564,615 | $(309,400) | $255,221 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.